Funding news
Flare Therapeutics logo

Flare Therapeutics Raises $85.0M Series C

Recently funded · $85.0M Series cHospitals and Health CareUSView source

Get the full Flare Therapeutics company profile

Access contacts, investors, buying signals & more

Open in Dashboard

A Series C funding round has brought $85.0M to Flare Therapeutics, the precision medicine company developing novel oncology treatments. The biotech firm specializes in drugging transcription factors, a challenging but promising target class, to create new therapies for cancer and other diseases.

Its lead candidate, FX-909, an orally available small molecule inhibitor of PPARG, has already shown clinical proof-of-concept in a Phase 1A study and is now actively dosing patients in Phase 1B for locally advanced or metastatic urothelial cancer. Flare also has a second lead program, FX-111, a degrader for the androgen receptor.

Other United States companies recently funded

View all

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#CompanyAmount
1
Shockwave Medical logo

Shockwave Medical

United States

$13.1B
2
NeuroEM Therapeutics logo

NeuroEM Therapeutics

United States

$7.2B
3
GRAIL logo

GRAIL

United States

$7.1B
4
Illumina logo

Illumina

United States

$7.1B
5
RemeGen Biosciences logo

RemeGen Biosciences

United States

$5.6B

Other recent Series c rounds

Companies that recently closed a Series c round.

#CompanyAmount
1
Cyware logo

Cyware

United States

$30.0M
2
Float logo

Float

Canada

$85.0M
3
New Limit Labs logo

New Limit Labs

$435.0M
4
Kapital Colombia logo

Kapital Colombia

Colombia

$471.1M
5
Prodrone logo

Prodrone

United States

$3.5M